Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9

被引:7
|
作者
Hummel, MA
Tracy, TS
Hutzler, JM
Wahlstrom, JL
Zhou, YH
Rock, DA
机构
[1] Pfizer Inc, Pfizer Global Res & Dev, St Louis Labs, Pharmacokinet Dynam & Metab, St Louis, MO 63017 USA
[2] Univ Minnesota, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
关键词
CYP2C9; drug interactions; fluorescent; inhibition; cytochrome b5;
D O I
10.1177/1087057105285612
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
7-Methoxy-4-trifluoromethylcoumarin (MFC) has been used extensively in high-throughput screens for the identification of potential CYP2C9 interactions. More recently, additional probes from Invitrogen have been used. Vivid 2C9 Green is the largest of the probes and has had limited prior characterization. The new series of probes differ significantly from MFC and were examined for their ability to identify interactions with 19 CYP2C9 substrates/inhibitors. The inhibition profiles depend largely oil the physical differences between the fluorescent probe substrates. Cytochrome b5 (cytb5) was also investigated for the ability to alter the inhibition profile of a given compound. The stoichometric addition of cyt b5 caused an increase in Vmax of MFC and Vivid 2C9 Green 4.4 and 1.7 times, respectively. Furthermore, cyt b5 imposes a steric component to the active site as the inhibition profiles were significantly affected in incubations with MFC. The addition of cyt b5 had limited impact on the inhibition profiles generated with Vivid 2C9 Green. The K,, of Vivid 2C9 Green increased from 1.2 +/- 0.2 mu M to 4.8 +/- 0.3 mu M as a result of cyt b5 addition. These results illustrate that multiple substrate probes may be necessary for screening drug-drug interaction in CYP2C9 and that cyt b5 effects can impart steric restraints on the CYP2C9 active site.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 50 条
  • [1] CYP2C9 protein interactions with cytochrome b5:: Effects on the coupling of catalysis
    Locuson, Charles W.
    Wienkers, Larry C.
    Jones, Jeffrey P.
    Tracy, Timothy S.
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (07) : 1174 - 1181
  • [2] Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics
    Rettie, AE
    Jones, JP
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 : 477 - 494
  • [3] Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions
    Zi, Jing
    Liu, Duan
    Ma, Pingping
    Huang, He
    Zhu, Juanli
    Wei, Dongqing
    Yang, Jin
    Chen, Chao
    DRUG METABOLISM AND PHARMACOKINETICS, 2010, 25 (04) : 343 - 350
  • [4] Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: Implication for clinical drug-drug interactions
    Song, Jin-Hui
    Sun, Dong-Xue
    Chen, Bin
    Ji, Dai-Hong
    Pu, Jie
    Xu, Jie
    Tian, Feng-De
    Guo, Lin
    JOURNAL OF BIOSCIENCES, 2011, 36 (05) : 879 - 885
  • [5] Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b5
    Gomez-Tabales, Javier
    Garcia-Martin, Elena
    Agundez, Jose A. G.
    Gutierrez-Merino, Carlos
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [6] Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment
    Gschwind, Liliane
    Rollason, Victoria
    Boehlen, Francoise
    Rebsamen, Michela
    Combescure, Christophe
    Gruenenwald, Michele
    Matthey, Alain
    Bonnabry, Pascal
    Dayer, Pierre
    Desmeules, Jules Alexandre
    PHARMACOGENOMICS, 2013, 14 (07) : 745 - 753
  • [7] Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b5
    Javier Gómez-Tabales
    Elena García-Martín
    José A. G. Agúndez
    Carlos Gutierrez-Merino
    Scientific Reports, 10
  • [8] Prediction of In Vivo Drug-Drug Interactions from In Vitro DataFactors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4
    Hayley S. Brown
    Aleksandra Galetin
    David Hallifax
    J. Brian Houston
    Clinical Pharmacokinetics, 2006, 45 : 1035 - 1050
  • [9] Prediction of in vivo drug-drug interactions from in vitro data -: Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4
    Brown, Hayley S.
    Galetin, Aleksandra
    Hallifax, David
    Houston, J. Brian
    CLINICAL PHARMACOKINETICS, 2006, 45 (10) : 1035 - 1050
  • [10] Drug-drug interactions induced by Linderane based on mechanism-based inactivation of CYP2C9 and the molecular mechanisms
    Wang, Kai
    Zhang, Tingting
    Rao, Jinqiu
    Peng, Ting
    Gao, Qing
    Feng, Xinchi
    Qiu, Feng
    BIOORGANIC CHEMISTRY, 2022, 118